US 12,226,332 B2
Obesity treatment
Peter Forsell, Bouveret (CH)
Filed by Peter Forsell, Bouveret (CH)
Filed on Jun. 16, 2022, as Appl. No. 17/841,733.
Application 17/841,733 is a continuation of application No. 16/296,605, filed on Mar. 8, 2019, granted, now 11,419,745.
Application 16/296,605 is a continuation of application No. 13/146,387, granted, now 10,226,372, issued on Mar. 12, 2019, previously published as PCT/SE2010/050101, filed on Jan. 29, 2010.
Claims priority of provisional application 61/213,813, filed on Jul. 17, 2009.
Claims priority of application No. PCT/SE2009/000047 (WO), filed on Jan. 29, 2009; application No. 0901007-5 (SE), filed on Jul. 17, 2009; application No. PCT/SE2009/000452 (WO), filed on Oct. 12, 2009; and application No. PCT/SE2009/051156 (WO), filed on Oct. 12, 2009.
Prior Publication US 2023/0033924 A1, Feb. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 5/00 (2006.01); A61B 1/273 (2006.01); A61B 1/313 (2006.01); A61B 17/00 (2006.01); A61B 17/04 (2006.01); A61B 17/064 (2006.01); A61B 17/068 (2006.01); A61B 17/08 (2006.01); A61B 17/30 (2006.01); A61B 17/32 (2006.01); A61B 17/34 (2006.01); A61F 2/04 (2013.01); A61N 1/36 (2006.01); A61B 1/04 (2006.01)
CPC A61F 5/0043 (2013.01) [A61B 1/2736 (2013.01); A61B 1/3132 (2013.01); A61B 17/00 (2013.01); A61B 17/00234 (2013.01); A61B 17/0469 (2013.01); A61B 17/064 (2013.01); A61B 17/068 (2013.01); A61B 17/08 (2013.01); A61B 17/30 (2013.01); A61B 17/320016 (2013.01); A61B 17/3423 (2013.01); A61B 17/3474 (2013.01); A61F 2/04 (2013.01); A61F 5/0003 (2013.01); A61F 5/0013 (2013.01); A61F 5/0026 (2013.01); A61F 5/003 (2013.01); A61F 5/0033 (2013.01); A61F 5/0036 (2013.01); A61F 5/004 (2013.01); A61F 5/0046 (2013.01); A61F 5/005 (2013.01); A61F 5/0069 (2013.01); A61F 5/0073 (2013.01); A61F 5/0079 (2013.01); A61F 5/0086 (2013.01); A61F 5/0089 (2013.01); A61N 1/36007 (2013.01); A61B 1/04 (2013.01); A61B 2017/00278 (2013.01); A61B 2017/00561 (2013.01); A61B 2017/00818 (2013.01); A61B 2017/00827 (2013.01); A61B 17/0682 (2013.01); A61B 2017/081 (2013.01); A61B 2017/306 (2013.01); A61B 2017/308 (2013.01); A61F 2002/044 (2013.01); A61F 2002/045 (2013.01); A61F 2005/0016 (2013.01); A61F 2005/002 (2013.01); A61F 2005/0023 (2013.01); A61F 5/0063 (2013.01); A61F 5/0076 (2013.01); A61F 2250/0001 (2013.01); A61F 2250/0004 (2013.01)] 18 Claims
OG exemplary drawing
 
1. An apparatus for treating obesity in a human or animal mammal patient, the apparatus comprising:
two or more volume filling device segments adapted to form an implantable volume filling device,
wherein the volume filling device is adapted to be at least substantially invaginated by a stomach wall portion of a patient,
wherein said volume filling device is adapted to be placed with an outer surface of the device resting against the stomach wall, such that the volume of the food cavity is reduced in size by a volume substantially exceeding the volume of the volume filling device, when the volume filling device is invaginated in the stomach wall, and
wherein said volume filling device is adapted to automatically disassemble into its volume filling device segments if the volume filling device leaves its implanted invaginated stomach position.